Little is known about the interaction between GLP-1 and the heptahelical core domain of GLP1R. Results: GLP-1 Asp 9 and Gly 4 interact with the evolutionarily conserved residues in extracellular loop 3. Conclusion: Ligand binding pocket formed by evolutionarily conserved residues in the GLP1R core domain. Significance: This study highlights the mechanism underlying high affinity interaction between GLP-1 and the binding pocket of the receptor.
GLP-1 potentiates glucose-dependent insulin secretion (2, 3) . In addition to its insulinotropic effects, GLP-1 promotes growth, survival, and differentiation of ␤-cells (4, 5) . Furthermore, GLP-1 slows down gastric emptying and promotes satiety. Thus, sustained activation of GLP1R results in weight loss (6, 7) . Because of these multiple beneficial effects that regulate blood glucose concentration and body weight, GLP-1 is a promising therapeutic agent for the treatment of type 2 diabetes mellitus and obesity. However, circulating GLP-1 is rapidly degraded by dipeptidyl peptide-IV and cannot be administered orally due to its peptidergic chemical nature (8, 9) . Thus, there is a great need to develop orally active small molecules that can act on GLP1R (10, 11) . The delineation of high affinity ligandreceptor binding and receptor activation will contribute to the development of such molecules.
GLP1R is a member of the class B G protein-coupled receptor (GPCR) family, which includes the glucagon receptor (GCGR) subfamily consisting of five members GCGR, GLP1R, GLP2R, glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-related peptide receptor (GCRPR) (12) (13) (14) (15) . In addition, growth hormone-releasing hormone receptor (GHRHR), secretin receptor (SCTR), vasoactive intestinal peptide receptor 1 (VPAC1 receptor (VPAC1R)), VPAC2R, and pituitary adenylate cyclase-activating polypeptide receptor (PAC1 receptor, PAC1R) share amino acid sequence similarity with members of the GCGR subfamily (13, 16, 17) . Class B GPCRs have a relatively long (ϳ120 amino acids) N-terminal extracellular domain (ECD) with an ␣-helix at the N terminus and two antiparallel ␤ sheets stabilized by three disulfide bonds and a salt bridge (18 -21) . The peptide ligands for this receptor family also share a common structure consisting of a random coiled N terminus followed by an ␣-helix (20, 22, 23) .
According to the two-domain model for class B GPCR activation, the second half of the ␣-helix of the peptide binds to the N-terminal ECD of the receptor (24 -26) . This induces a secondary interaction between the N-terminal moiety of the peptide and the receptor core domain consisting of transmembrane helices (TMHs) and extracellular loops (ECLs). This secondary interaction confers receptor activation and G protein coupling (27) (28) (29) . The interactions between the N-terminal ECD of GLP1R and the second half of the ␣-helical part of GLP-1 and exendin-4 have been elucidated by x-ray crystallography (20, 22) . However, a crystal structure for the ligandbound receptor core domain is not yet available. This structure would provide useful information for understanding the mechanism of ligand-induced receptor activation.
Alanine scanning analysis revealed that His 1 , Gly 4 , Thr 7 , and Asp 9 in the N-terminal portion of GLP-1 are important for receptor binding and activation (30, 31) . Recently, by using chimeric GLP1R/GIPR together with chimeric GLP-1/GIP peptides, we identified interactions of His  1 and Thr  7 of GLP-1 with  Ile  196 /Lys  197 at TMH2, Met  233 at ECL1, and Asn 302 at ECL2 of GLP1R (32) . These results demonstrated the evolutionary pressure to conserve critical residues for ligand binding and activation of GLP1R (33) . However, this study did not fully account for the ligand binding pocket of GLP1R, which may require additional residues, probably located at ECL3, for interaction with Gly 4 and Asp 9 of GLP-1. In the present study we constructed chimeric GLP1Rs in which the GLP1R ECL3 was replaced with the VPAC1R ECL3, which has a markedly different amino acid sequence. This chimeric receptor responded poorly to GLP-1, showing the importance of ECL3 for ligand-induced receptor activation. Additional experiments in which single amino acid mutations were introduced into GLP1R ECL3 revealed that the evolutionarily conserved basic residue Arg 380 and the flanking hydrophobic residues Leu 379 and Phe 381 were likely to mediate interactions with Gly 4 and Asp 9 of GLP-1. Based on this observation and our previous result (33), we propose that the ligand binding pocket of GLP1R is formed by evolutionarily conserved residues in TMH2, ECL1, ECL2, and ECL3.
EXPERIMENTAL PROCEDURES
Peptides-Wild-type GLP-1, glucagon, GCRP, GIP, GLP-2, and modified peptides were synthesized by AnyGen (Gwangju, Korea). The amino acid sequences of these peptides are shown in Table 1 and Fig. 7A .
Plasmids-The cDNA encoding human GLP1R was originally purchased from Benebiosis (Seoul, Korea) and subcloned into the mammalian expression vector pcDNA3 (Invitrogen).
Human VPAC1R, GLP2R, and GCGR in pcDNA3 were obtained from BRNscience Inc. (Seoul, Korea). Human GIPR was kindly provided by Dr. Bernard Thorens (Institute of Pharmacology and Toxicology, Switzerland). Chicken GCRPR was cloned from a White Leghorn hen brain cDNA library (15) . The CRE-luc vector, which contains four copies of CRE (TGACGTCA), was obtained from Stratagene (La Jolla, CA).
Construction of Chimeras and Mutants-To swap domains between GLP1R and VPAC1R, individual cDNA fragments of interest were amplified by PCR with Pfu polymerase (ELPIS Biotech., Daejeon, Korea) and two specific primers. One primer corresponded to the 5Ј or 3Ј end of the receptor cDNAs, and the other primer corresponded to the region of overlap between the two receptors. One fragment was obtained from GLP1R, and the other was from VPAC1R. Both fragments were subjected to a second round of PCR to generate chimeric cDNAs. All of the chimeric constructs were cloned into the pcDNA3 expression vector at the HindIII and XhoI sites. The single and double mutants were constructed by PCR-based site-directed mutagenesis and cloned into pcDNA3 at the HindIII and XhoI sites. The DNA sequences of the chimeras and mutants were verified by automatic sequencing.
Cell Transfection and Luciferase Assays-HEK293T cells were maintained in Dulbecco's modified Eagle's media (DMEM) in the presence of 10% fetal bovine serum. For luciferase assays, cells (2.5 ϫ 10 4 ) were plated in 48-well plates 1 day before transfection and transfected with Effectene reagent (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. Approximately 48 h after transfection, cells were treated with the respective ligands for 6 h. Cells were harvested 6 h after ligand treatment. Luciferase activities were determined in cell extracts with a luciferase assay system according to the standard methods for the Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooski, VT).
Binding Assay-GLP-1 and [Arg 9 ]GLP-1 were radioiodinated by the chloramine-T method and purified by chromatography on a Sephadex G-25 column (Sigma) in 0.01 M acetic acid and 0.1% bovine serum albumin (BSA). Cells (1.2 ϫ 10 5 ) were transfected with wild-type or mutant receptors (300 ng of DNA/well in 12-well plates) with Effectene (Qiagen). Fortyeight hours later, cells were washed and incubated for 1 h at 37°C with binding buffer (serum-free DMEM with 0.1% BSA, pH 7.4) containing 100,000 cpm 125 I-Labeled ligand (equivalent to ϳ30 nM) in the presence of various concentrations of cold ligand. Relative expression levels of receptors were determined using 500,000 cpm 125 I-labeled ligand (a concentration for submaximal binding toward the wild-type receptor) in the presence of 10 M cold ligand. Cells were washed twice with icecold Dulbecco's PBS. The radioactivity of the cell lysate resolved in 1% SDS and 0.2 M NaOH was determined on a Wallac 1489 Wizard 3 ␥-counter (PerkinElmer Life Sciences).
Data Analysis-Data analysis was performed by nonlinear regression with a sigmoid dose-response curve. Agonist concentrations that induced half-maximal stimulation (EC 50 ) were calculated with GraphPad PRISM4 software (GraphPad Software Inc., San Diego, CA). All data are presented as the means Ϯ S.E. of at least three independent experiments. Group means were compared by Student's t test or one-way analysis of and Asp 9 of GLP-1 ϳ Arg 380 of GLP1R. An ␣-helical secondary structure was enforced for each TMH. The variable target function method with the very thorough option and molecular dynamics optimization with the thorough option were applied during model building. All structural analyses and figure preparations were performed with ICM Version 3.7-3b (Molsoft, San Diego, CA) and Ligplot ϩ Version 1.4.3 (36) . The electrostatic potential of the protein surface was calculated with the REBEL method, which solves the Poisson equation with the boundary element method (37) . Structures for the mutants were generated by exchanging residues with other amino acids and minimizing energy locally.
RESULTS

The Second Half of GLP1R ECL3 Interacts with GLP-1-We
previously exchanged TMH2, ECL1, and ECL2 of GLP1R and GIPR to create chimeric receptors. The peptide ligands for these receptors showed significantly altered potencies and affinities for the receptor chimera (32) , demonstrating that residues in TMH2, ECL1, and ECL2 contribute to interactions between GLP-1 and GLP1R. However, exchanging ECL3 of GLP1R with that of GIPR did not affect the potency of GLP-1. This is likely due to a relatively high degree (47%) of sequence similarity between ECL3 of GLP1R and that of GIPR. Indeed, the ECL3 regions of GLP1R and its paralogous receptors GIPR, GLP2R, GCGR, and GCRPR exhibit considerable similarities in amino acid length and sequence (32) . In our previous study with GLP1R/GIPR chimeric receptors, we were unable to identify the residues in GLP1R ECL3 that interact with the peptide ligand. In this study we employed VPAC1R, which is phylogenetically closer to the GLP1R subfamily than other class B GPCR subfamilies, such as parathyroid hormone receptor, corticotropin-releasing hormone receptor, and calcitonin receptor subfamilies (13) . Similarly, the amino acid sequence and secondary structure of the VIP peptide family are very similar to those of the GLP-1 peptide family (13) .
To determine if ECL3 contributes to the interaction between GLP1R and GLP-1, the sequence from the start of ECL3 to the C terminus of GLP1R was replaced with that of VPAC1R to create the G/V [E3-C] receptor (Fig. 1) . Cells expressing the G/V [E3-C] receptor were treated with increasing concentrations of GLP-1. This replacement greatly reduced the potency of GLP-1. In contrast, replacement with the GIPR ECL3 to C-terminal regions (GL/I6) (32) did not alter the potency of GLP-1 (Fig. 1) . This result suggests that the sequence comprising ECL3 to TMH7 of GLP1R is important for GLP-1 interaction.
The GLP-1-interacting motifs in ECL3-TMH7 were further narrowed down by generating additional GLP1R/VPAC1R chimeric receptors. Chimeric receptors included the VPAC1R sequence from the second half (b) of ECL3 to the C terminus (G/V [E3b-C] ), from TMH7 to the C terminus of VPAC1R (G/V [T7-C] ), the entire VPAC1R ECL3 (G/V [E3ab] ), or the second half of VPAC1R ECL3 (G/V [E3b] ) (Fig. 2) . The potency of GLP-1 for each of the chimeric receptors was measured. G/V [T7-C], which retained the second half of GLP1R ECL3, responded to GLP-1 in a similar manner to that of the wild-type GLP1R (Fig. 2) . However, chimeric receptors
, and G/V [E3b] , in which the second half of GLP1R ECL3 was absent, responded very poorly to GLP-1 (Fig.  2) . These results suggest that the second half of ECL3 mediates the interaction of GLP1R with GLP- 381 , and Leu 384 in the second half of GLP1R ECL3 are found in the corresponding positions of GIPR but not in VPAC1R, which has Lys, Pro, Glu, and Met in these positions, respectively (Fig. 1B) . To investigate whether these amino acid residues were responsible for specific interactions with GLP-1, the residues were substituted for those in G/V [E3b] , which had a marginal response to GLP-1. Single residue-substituted mutants, such as K379L, P380R, and E381F in G/V [E3b] , increased the GLP-1 potency compared with that of G/V [E3b] . The Arg 380 substitution ([P380R]G/V [E3b] ) showed the greatest increase in GLP-1 potency out of all of the single residue mutations (Fig. 3) . However, the M384L mutant did not increase the potency of GLP-1. Compared with [P380R]G/V [E3b] , the additional substitutions, K379L/P380R (KP-LR) and K379L/P380R/E381F (KPE-LRF), further increased the GLP-1 potency by 10-and 100-fold, respectively (Fig. 3) . K379L/P380R/E381F exhibited ligand-responsive behavior similar to that of wild-type GLP1R. However, additional mutations of Met to Leu 384 did not significantly augment the potency of GLP-1 (Fig. 3) . These results suggest that the specific structure formed by basic Arg 4 and Asp 9 in GLP-1 interacted with residues in ECL3 of GLP1R. To address this possibility, we generated mutant GLP1Rs in which the basic Arg 380 was changed to acidic Asp (R380D) or neutral Gly (R380G), and hydrophobic Leu 379 and Phe 381 were modified to either basic (L379R and F381R) or acidic (L379E and F381E) residues (Fig. 4) . All of the mutants except for F381R exhibited decreased responsiveness and affinity to GLP-1 ( Table 2 ). In particular, the GLP-1 potency of the R380D mutant receptor was reduced by Ͼ1000-fold compared with that of wild-type GLP1R (Fig. 4) . In contrast, the basic Arg substitution in F381R GLP1R maintained a high affinity for GLP-1. To identify the amino acid residues in GLP-1 that interact with Arg 380 of GLP1R, we generated modified GLP-1 peptides in which Gly 4 was replaced with acidic (Asp and Glu) or basic (His, Lys, and Arg) residues and Asp 9 was changed to a basic Lys or Arg residue or to an acidic Glu ( Table 1 ). The potencies of the modified peptides were determined for wild-type and R380D mutant GLP1R ( Table 2 ). All of the modified GLP-1 peptides except for [Glu 9 ]GLP-1 exhibited substantially decreased potencies for wild-type GLP1R (Table 2 and Fig. 5A ). These data indicate the importance of Gly 4 ]GLP-1 had increased potencies for R380D GLP1R compared with wild-type GLP-1. Among all of the peptides, the potency of [Arg 9 ]GLP-1 on R380D GLP1R was the greatest (Table 2 and Fig. 5B) . We have confirmed these results using a pGlosensorTM-22F system that directly examines cAMP pro- a , versus wild-type GLP1R (p Ͻ 0.05).
FIGURE 3. Identification of GLP-1-interacting residues in the second half of GLP1R ECL3. A, the potency of GLP-1 toward chimeric GLP1R, which has the second half of VPAC1R ECL3 (G/V [E3b] ), or mutant G/V [E3b]
, into which residues from GLP1R ECL3 were introduced. 
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FEBRUARY 27, 2015 • VOLUME 290 • NUMBER 9 duction in response to ligand stimulation (14) . The results (data not shown) are similar in tendency to that of Fig. 5 such that the mutant peptides showed decreased potency and efficacy toward wild-type receptors while exhibiting higher potency or efficacy toward R380D GLP1R than wild-type peptide. These changes represent reciprocal mutations of charged residues in the ligand and receptor, and the result suggests a possible interaction of Asp 9 of GLP-1 with Arg 380 of GLP1R. To corroborate this, we performed a ligand-receptor binding assay. Iodinated [Arg 9 ]GLP-1 exhibited significantly lower binding affinity for wild-type GLP1R but relatively high affinity for R380D, which had low affinity for wild-type GLP-1 (Fig. 5, C and D) . We also examined the potency and affinity of the mutant GLP-1 peptides for the mutant receptors, L379R, L379E, F381R, and F381E (Table 2 ). However, none of the mutant peptides exhibited potencies and affinities higher than that of wild-type GLP-1 toward the mutant receptors. These results indicated that Leu 379 and Phe 381 do not directly interact with the ligand but may be important for maintaining a receptor conformation that favors ligand binding. To determine the expression levels of wild-type and mutant receptors, we performed a binding assay using submaximal concentration of radiolabeled ligands (Table  2) . Additionally, Western blot and confocal microscope for GFP-conjugated wild-type and mutant receptors reveals that all receptors seem to be stably expressed in the cells (data not shown).
Molecular Modeling Shows Direct Interaction between Asp 9
of GLP-1 and Arg 380 of GLP1R-The GLP-1-GLP1R interaction was examined on a three-dimensional atomic scale using a homology model. The crystal structures of the ligand-bound ECD of human GLP1R and human GIPR served as structural templates of the ECD modeling of GLP1R. The core domain structure was built based on the crystal structures of two class B GPCRs, human GCGR (38) and corticotropin-releasing factor 1 receptor (39) . Although these two crystal structures represent inactive structures with antagonists, a lesson from the class A GPCR structures is that there is no significant structural difference in the ligand binding sites between agonist-bound and antagonist-bound structures, whereas there are large conformational changes in the G protein binding regions (40) .
Sequence alignment between GLP1R and the GPCRs of the crystal structures was done manually with predicted TMHs and evolutionarily conserved residues. Seven distance restraints between GLP-1 and GLP1R were introduced during homology modeling as listed under "Experimental Procedures," and extensive optimization was performed.
The final model provided interesting explanations for the effects of the GLP1R mutations. Initially, GLP1R Arg 380 was located near Asp 9 and Gly 4 of GLP-1 (Fig. 6A) . The interaction between the side chains of GLP1R Arg 380 and GLP-1 Asp 9 is likely due to an electrostatic attraction. Electrostatic surface charge analyses of wild-type and R380D GLP1R revealed the importance of the ionic charge at position 380 (Fig. 6, B and C) . ]GLP-1 has a very low potency and affinity to the wildtype receptor, but it has a relatively high potency and affinity toward the R380G mutant receptor ( , and Leu 388 of TMH7 (Fig. 6D) . Thus, mutation of Leu 379 to a bulky Arg may substantially alter receptor conformation and attenuate ligand binding (Fig. 4) . Our model, however, suggests that the side chain of Phe 381 was orientated away from the binding pocket and interacted with only several residues of ECL3, enduring a substantial change to Arg 381 (Fig. 6E) . The combined cationic nature of Arg at 380 and 381 is well tolerated but demonstrates preference of Asp 9 relative to Glu (Arg  362 ) . Similarly, Gly at position 4 and acidic residue Asp or Glu at position 9 are common for GLP-1 and its related peptides, glucagon, GCRP, GLP-2, and GIP (Fig. 7A) . This observation suggests that the GLP-1 peptide and receptor families may share a common mechanism of interaction between acidic Asp/Glu 9 and/or Gly 4 of the peptide and basic Arg 380 in ECL3 of the corresponding receptor. To address this possibility, we generated mutant GCGR, GCRPR, GLP2R, and GIPR, in which the Expression of receptors is shown as % maximal level of wild-type GLP1R. Binding affinity is presented as log IC 50 . The potencies of the modified GLP-1 peptides are shown as log EC 50 . The Emax values of each mutant in response to modified peptides were not significantly different from the Emax value of wild-type GLP1R to GLP-1. basic Arg (or Lys) in ECL3 was replaced with Asp. Wild-type and mutant receptors were treated with the corresponding peptide ligands or mutant peptides, in which the acidic residue at position 9 was changed to Arg. All of the [Arg 9 ]peptide showed decreased potencies for the corresponding wild-type receptors, GCGR, GCRPR, GIPR, and GLP2R (Fig. 7, B-E) . Mutation of Arg 378 to Asp in GCGR greatly reduced the potency of wildtype glucagon. Interestingly, the mutant [Arg 9 ]glucagon exhibited higher potency for this mutant receptor compared with wild-type glucagon (Fig. 7B) . Likewise, mutation of Arg 379 to Asp in GCRPR decreased the potency of wild-type GCRP but increased the potency of [Arg 9 ]GCRP by 10-fold compared with that of wild-type GCRP (Fig. 7C) 
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DISCUSSION
The interaction between the N terminus of GLP-1 and the core domain of GLP1R is important for ligand-induced receptor activation (41, 42) . Thus, many approaches, such as alanine scanning, photoaffinity labeling, and molecular docking, have been attempted to identify specific amino acids that are required for this interaction (28, (43) (44) (45) (46) (47) (24, 28, 43, 44, 48) . However, these studies do not explain how individual residues in the peptide interact with residues in the receptor. Furthermore, most of these residues are highly conserved within the class B GPCRs, including VPACR, CRFR, CALCR, and PTHR. This suggests that these residues are more important for maintaining the basic receptor architecture than for conferring selective ligand interaction (45, 47, 49) . Experiments with photolabile probes for GLP-1 provide only partial information regarding the spa- tial approximation of the residues in the peptide and receptor that interact with each other. Phe 6 of GLP-1 is in close proximity to Tyr 145 of GLP1R according to that study (46) . Recent results from another study that used the same method showed discrepancies compared with crystallography experiments. For example, although GLP-1 Ala 18 was proposed to be located close to Glu 133 of the ECD of GLP1R by photoaffinity labeling (45), the ligand-bound crystal structure of the GLP1R ECD shows a hydrophobic interaction between GLP-1 Ala 18 and Leu 32 of the ECD (20, 21) . Molecular docking studies with biochemical analyses have suggested possible ligand binding pockets in the GLP1R core domain (47, 50, 51) . However, these modeling approaches failed to provide a common consensus for the ligand binding pocket. Instead, these approaches differed in their identification of residues that contact the ligand. Thus, stricter biochemical analyses with an appropriate strategy may be helpful for constructing a more reliable ligand-bound receptor model.
Although GLP-1 and its related peptides share a high degree of sequence identity and structural similarity, they generally exhibit specific binding to their own receptors with some crossreactivity toward paralogous receptors (32, 52) . This observation suggests that there are distinct amino acid residues among paralogs of the peptide and receptor that mediate selective interactions with their own partners. Thus, our study is based on the concept of coevolution of the peptide ligand and receptor family. Evolutionary pressure preserves the amino acid residues that are essential for the basic protein structure and for primary interactions between ligand and receptor family members. Specific changes in the amino acid sequence permit selective interaction between a ligand-receptor pair (53) (54) (55) (56) (57) . In the former case, residues are conserved across paralogous members. However, in latter case, residues are conserved within orthologous members and differ from those of paralogs (33) . This hypothesis is supported by recent crystal structures for the ligand-bound ECD of GLP1R and GIPR (18, 20, 21) and by molecular docking models for the ligand-bound ECD of GCGR and GLP2R (58, 59) . The hydrophobic face of the peptides is formed by the conserved residues, Phe 22 , Ile/Val 23 , Trp 25 , and Leu 26 , and points toward the hydrophobic binding cavity of the ECD. The ECD hydrophobic binding cavity is formed by conserved hydrophobic residues, which are localized primarily in the N-terminal ␣-helix, at the end of the ␤2 strand, and in the loop between the ␤3 and ␤4 strands. These evolutionarily conserved residues may contribute to primary interactions across these peptide and receptor family members (27, 52 ). In contrast, the residues located at positions 16 -20 vary across paralogous peptides but are conserved among orthologs of each paralog (33) . These conserved residues may account for the selectivity and strong interaction between each peptide-receptor pair (18, 21) .
In the N-terminal portion of GLP-1, His
